Agile Therapeutics's competitors

Agile Therapeutics's competitors include Eli Lilly, AstraZeneca, TherapeuticsMD and AEterna Zentaris
Add company...
Agile Therapeutics
Agile Therapeutics is the pharmaceutical company developing contraceptive healthcare products for women.
Eli Lilly
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
AstraZeneca
AstraZeneca, a global pharmaceutical company, discovers, develops, manufactures and markets prescription medicines.
TherapeuticsMD
TherapeuticsMD is a pharmaceutical company focused on producing generic prescriptions and over-the-counter products for women.
AEterna Zentaris
AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Companys product pipeline
Founding Date
Founding Date
1997
Founding Date
1876
Founding Date
1999
Founding Date
2008
Founding Date
N/A
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Princeton, US HQ
Locations
Indianapolis, US HQ
Exeter, GB
Vernier, CH
Yanbian, CN
México D.F., MX
Dali, CN
Hohhot, CN
see more
Locations
Cambridge, GB HQ
Sydney, AU
Brussels, BE
Winnipeg, CA
Mississauga, CA
Montreal, CA
Windsor, CA
see more
Locations
Boca Raton, US HQ
Locations
Summerville, US HQ
Frankfurt Am Main, DE
Employees
Employees
19 12% increase
Employees
41,975
Employees
59,700
Employees
159
Employees
56
Valuation ($)
Valuation ($)
88.9 m
Valuation ($)
83.9 b
Valuation ($)
87.4 b
Valuation ($)
1.2 b
Valuation ($)
30.6 m
Facebook likes
Facebook likes
N/A
Facebook likes
147.6 k
Facebook likes
25.6 k
Facebook likes
90
Facebook likes
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
69
Twitter followers
141.3 k
Twitter followers
149
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$21.2b (FY, 2016)
Revenue (est.)
$21.3b (FY, 2016)
Revenue (est.)
$19.4m (FY, 2016)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$5.7b (FY, 2016)
Cost of goods
$4.1b (FY, 2016)
Cost of goods
$4.2m (FY, 2016)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$15.6b (FY, 2016)
Gross profit
$17.2b (FY, 2016)
Gross profit
$15.2m (FY, 2016)
Gross profit
N/A
Net income
Net income
($28.3m) (FY, 2017)
Net income
$2.7b (FY, 2016)
Net income
$3.4b (FY, 2016)
Net income
($89.9m) (FY, 2016)
Net income
N/A

Operating

Phase I Trials Products
Phase I Trials Products
3 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
41 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
1 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
36 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
19 (FY, 2016)
Phase III Trials Products
27 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
66 (FY, 2016)
Projects in R&D Pipeline
132 (FY, 2016)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles